University of Hertfordshire

From the same journal

By the same authors

Standard

Systematic review of medicines-related problems in adult patents with atrial fibrillation on direct oral anticoagulants. / Alewairdhi, Huda; Umaru, Nikkie; Aslanpour, Zoe.

In: British Journal of Pharmacy, Vol. 2, No. 1, 16.10.2017.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{3cc0988e47914969b8fd94b80e7d4527,
title = "Systematic review of medicines-related problems in adult patents with atrial fibrillation on direct oral anticoagulants",
abstract = "New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice.",
author = "Huda Alewairdhi and Nikkie Umaru and Zoe Aslanpour",
note = "Alewairdhi et al (2017). Published by University of Huddersfield Press. This is an Open Access article (https://creativecommons.org/licenses/by/4.0/).",
year = "2017",
month = oct,
day = "16",
doi = "10.5920/bjpharm.2017.07",
language = "English",
volume = "2",
journal = "British Journal of Pharmacy",
number = "1",

}

RIS

TY - JOUR

T1 - Systematic review of medicines-related problems in adult patents with atrial fibrillation on direct oral anticoagulants

AU - Alewairdhi, Huda

AU - Umaru, Nikkie

AU - Aslanpour, Zoe

N1 - Alewairdhi et al (2017). Published by University of Huddersfield Press. This is an Open Access article (https://creativecommons.org/licenses/by/4.0/).

PY - 2017/10/16

Y1 - 2017/10/16

N2 - New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice.

AB - New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice.

U2 - 10.5920/bjpharm.2017.07

DO - 10.5920/bjpharm.2017.07

M3 - Article

VL - 2

JO - British Journal of Pharmacy

JF - British Journal of Pharmacy

IS - 1

ER -